Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 7/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855888 | 0.96 | GPR52 (0.52) | GPR52CLK1METAP2SHMT1 | |
| SCHEMBL3217370 | 0.93 | GPR52 (0.56) | GPR52CLK1METAP2SHMT1AURKA | |
| SCHEMBL1852756 | 0.91 | GPR52 (0.56) | GPR52 | |
| SCHEMBL7965937 | 0.90 | GPR52 (0.51) | GPR52CLK1AURKARPS6KB1 | |
| SCHEMBL1851933 | 0.90 | GPR52 (0.53) | GPR52CLK1METAP2SHMT1PARP1 | |
| SCHEMBL3204559 | 0.88 | GPR52 (0.63) | GPR52CLK1METAP2AURKA | |
| SCHEMBL3219164 | 0.87 | GPR52 (0.52) | GPR52CLK1SHMT1PARP1PRF1 | |
| SCHEMBL1851960 | 0.86 | GPR52 (0.55) | GPR52NPC1RAB9A | |
| SCHEMBL1855891 | 0.86 | GPR52 (0.57) | GPR52 | |
| SCHEMBL1849783 | 0.84 | GPR52 (0.56) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885CLK1 4628/4885METAP2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.